RÉSUMÉ
Neuroleptic malignant syndrome (NMS) is a severe adverse reaction associated with neuroleptic or antipsychotic drugs. This case report discusses a 43-year-old man with a history of bipolar disorder and polysubstance abuse who presented with altered mental status, autonomic dysfunction, and muscular rigidity. The patient had recently started on ziprasidone, a second-generation antipsychotic, leading to an atypical presentation of NMS. Unlike classic findings associated with NMS induced by first-generation antipsychotics, this case lacked high fever, lead pipe rigidity, or elevated creatine kinase levels greater than 1000 on initial presentation. The delay in diagnosis was attributed to the milder symptoms and absence of typical findings, resulting in extensive diagnostic workup and interventions. The patient responded positively to treatment with lorazepam based on the Woodbury severity stage guidelines. This case underscores the complexity of diagnosing NMS induced by second-generation antipsychotics and highlights the need for awareness and tailored treatment approaches for atypical presentations.
Sujet(s)
Neuroleptiques , Syndrome malin des neuroleptiques , Pipérazines , Thiazoles , Humains , Syndrome malin des neuroleptiques/diagnostic , Syndrome malin des neuroleptiques/étiologie , Mâle , Adulte , Neuroleptiques/effets indésirables , Thiazoles/effets indésirables , Pipérazines/effets indésirables , Trouble bipolaire/traitement médicamenteux , Lorazépam/usage thérapeutiqueRÉSUMÉ
Neuroleptic malignant syndrome (NMS), which most often occurs after the use of antipsychotics, is a rare but life-threatening condition. In this article, a 56-year-old male patient with a diagnosis of bipolar affective disorder (BPD) who developed NMS after a COVID-19 infection will be presented. The patient had been brought to the emergency room with high fever, fatigue, and slowness of movements that had been going on for two days. The examination revealed tachycardia, tachypnea, lethargy and rigidity. Upon further investigation the COVID-19 test came out positive and the serum levels of creatine kinase were considerably high. He was admitted to the psychiatric ward with diagnoses of COVID-19 infection and NMS. COVID-19 infection might have been a risk factor for NMS in this patient. Especially in patients who are taking antipsychotic drugs, if COVID-19 is present, the risk of NMS should be taken into consideration. Keyword: COVID-19, Neuroleptic Malignant Syndrome, Risperidone, Antipsikotik, Enfeksiyon.
Sujet(s)
Neuroleptiques , COVID-19 , Syndrome malin des neuroleptiques , Mâle , Humains , Adulte d'âge moyen , Syndrome malin des neuroleptiques/diagnostic , Syndrome malin des neuroleptiques/étiologie , COVID-19/complications , Neuroleptiques/effets indésirables , Rispéridone/effets indésirablesRÉSUMÉ
BACKGROUND: Significant elevation of creatine kinase levels (above three digits) and leucocytosis in the absence of muscle rigidity, tremors, or autonomic dysfunction can pose a real challenge in the context of antipsychotic treatment as an early herald of neuroleptic malignant syndrome. CASE PRESENTATION: We present here two cases of adult male patients of Black British heritage, ages 51 years and 28 years, respectively. Both received a diagnosis of schizoaffective disorder and presented with massive increase of creatine kinase blood level after aripiprazole depot administration, one with pernicious increase associated with silent neuroleptic malignant syndrome, and the second with asymptomatic benign enzyme elevation. CONCLUSION: Though aripiprazole use is less likely to cause neuroleptic malignant syndrome, on rare occasions it can produce massive symptomatic or asymptomatic increase in serum creatine kinase enzyme levels, raising the need for close monitoring, especially at the initial doses of the drug.
Sujet(s)
Neuroleptiques , Syndrome malin des neuroleptiques , Troubles psychotiques , Adulte , Humains , Mâle , Aripiprazole , Syndrome malin des neuroleptiques/diagnostic , Syndrome malin des neuroleptiques/traitement médicamenteux , Syndrome malin des neuroleptiques/étiologie , Neuroleptiques/usage thérapeutique , Troubles psychotiques/traitement médicamenteux , Creatine kinaseRÉSUMÉ
Neuroleptic malignant syndrome (NMS) is a rare yet severe condition typically associated with antipsychotic medications. Here, we present a case of NMS induced by prochlorperazine in a 76-year-old male with multiple comorbidities, aiming to delineate its clinical manifestation, diagnostic complexities, and treatment approaches. Our methodology involved a thorough documentation of the patient's medical history, initial symptoms, physical examination findings, laboratory results, diagnostic processes, and subsequent therapeutic interventions. The patient exhibited classic NMS symptoms, including fever, altered mental status, autonomic dysregulation, and generalized rigidity, consistent with diagnostic criteria. Notably, laboratory investigations failed to reveal the typical abnormalities often seen in NMS cases, highlighting the diverse presentation of this syndrome. Management strategies primarily focused on benzodiazepines and amantadine, leading to a gradual improvement in symptoms and eventual resolution of NMS. This underscores the critical role of early recognition and appropriate pharmacotherapy in managing prochlorperazine-induced NMS, even at standard dosage levels. The absence of characteristic laboratory findings in NMS poses challenges in diagnosis, necessitating a comprehensive clinical assessment for accurate identification. Moreover, this case emphasizes the need for further research to better understand the pathophysiology of prochlorperazine-induced NMS and optimize treatment protocols. In conclusion, our case report sheds light on the complexities surrounding NMS induced by prochlorperazine, emphasizing the importance of vigilant monitoring and tailored therapeutic strategies in mitigating its potentially life-threatening consequences.
Sujet(s)
Neuroleptiques , Syndrome malin des neuroleptiques , Prochlorpérazine , Humains , Syndrome malin des neuroleptiques/diagnostic , Syndrome malin des neuroleptiques/étiologie , Mâle , Prochlorpérazine/usage thérapeutique , Prochlorpérazine/effets indésirables , Sujet âgé , Neuroleptiques/effets indésirablesRÉSUMÉ
An incarcerated male patient with a psychiatric history of schizoaffective disorder presented to the emergency department with muscle rigidity and mutism after receiving a 150 mg haloperidol decanoate injection. At the peak of his illness, symptoms included muscular rigidity, mutism, excessive drooling, an altered level of consciousness, tachycardia, diaphoresis and tremors. Atypical neuroleptic malignant syndrome (NMS) was diagnosed after discrediting similar illnesses through clinical reasoning, laboratory and imaging studies. He was successfully treated during a 40-day hospitalisation with lorazepam, amantadine, methocarbamol and supportive care. This case represents an atypical presentation of NMS due to the patient's lack of fever development. Nonetheless, he satisfied many other criteria, most notably rapid symptom onset after receiving a first-generation antipsychotic medication. The case also provides an opportunity to discuss the prevalence of psychiatric illness among the US incarcerated population and incarceration as a risk factor for developing NMS.
Sujet(s)
Neuroleptiques , Mutisme , Syndrome malin des neuroleptiques , Prisonniers , Mâle , Humains , Syndrome malin des neuroleptiques/diagnostic , Syndrome malin des neuroleptiques/étiologie , Syndrome malin des neuroleptiques/traitement médicamenteux , Neuroleptiques/effets indésirables , DémographieRÉSUMÉ
BACKGROUND: Anti-N-methyl-D-aspartate receptor encephalitis (ANMDARE) is a neuroimmunological disorder that frequently improves with immunotherapy. Symptomatic treatment with antipsychotics is common in the early stages when psychiatric symptoms predominate, and their use has been associated with serious side effects including neuroleptic malignant syndrome (NMS). The observation of an adverse response to antipsychotics, raising the suspicion of NMS, has been included as a criterion for possible autoimmune psychosis. METHODS: This case-control study included patients who received antipsychotics before referral to the National Institute of Neurology and Neurosurgery of Mexico, where they were diagnosed as having definite ANMDARE, and patients with ANMDARE who did not receive antipsychotics before referral. The neurologic and systemic features that are used to measure an adverse response to antipsychotics, raising the suspicion of NMS, were measured in both groups, including akinesia, autonomic instability, generalized rigidity, elevated concentrations of creatine phosphokinase, and hyperthermia. A logistic regression analysis was used to determine the relationship between the previous use of antipsychotics and the occurrence of NMS-like reactions. RESULTS: A total sample of 112 patients with definite ANMDARE were included in the study. Fifty patients received antipsychotics before being referred to our institution. In this group, thirty-six patients (72%) were initially classified as having an adverse response, raising the suspicion of NMS, with the following features: akinesia (64%), autonomic instability (58%), generalized rigidity (52%), elevated concentrations of creatine phosphokinase (50%), and hyperthermia (14%). Six patients fulfilled the criteria for NMS (12%). The comparison with patients who did not receive antipsychotics before the clinical assessment did not show a significant difference between groups regarding the frequency of akinesia, autonomic instability, generalized rigidity, elevated concentrations of creatine phosphokinase, or hyperthermia. Among different antipsychotics, only haloperidol was significantly associated with generalized rigidity as compared to patients who did not receive antipsychotics. CONCLUSIONS: Our study supports previous observations about the high frequency of autonomic dysfunction, hyperthermia, tachycardia, rigidity, and elevated creatine phosphokinase levels in patients with anti-NMDAR encephalitis following the administration of antipsychotic medications. Nevertheless, our study does not suggest a causal link between atypical antipsychotics and the onset of these neurological symptoms, as they were equally frequent among the group of patients who did not receive antipsychotic treatment.
Sujet(s)
Encéphalite à anticorps anti-récepteur N-méthyl-D-aspartate , Neuroleptiques , Syndrome malin des neuroleptiques , Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Encéphalite à anticorps anti-récepteur N-méthyl-D-aspartate/complications , Neuroleptiques/effets indésirables , Neuroleptiques/usage thérapeutique , Études cas-témoins , Mexique/épidémiologie , Syndrome malin des neuroleptiques/traitement médicamenteux , Syndrome malin des neuroleptiques/étiologieRÉSUMÉ
No disponible
Sujet(s)
Humains , Femelle , Adulte d'âge moyen , Syndrome malin des neuroleptiques/étiologie , Benzodiazépines/administration et posologie , Benzodiazépines/effets indésirables , Facteurs de risque , Palmitate de palipéridone/effets indésirables , Performance psychomotrice , Association triméthoprime-sulfaméthoxazole/usage thérapeutique , Diagnostic différentielRÉSUMÉ
No disponible
Sujet(s)
Sujet âgé , Humains , Mâle , Syndrome malin des neuroleptiques/diagnostic , Syndrome malin des neuroleptiques/étiologie , Creatine kinase/sang , Syndrome malin des neuroleptiques/traitement médicamenteux , Électroconvulsivothérapie , Neuroleptiques/usage thérapeutique , Trouble bipolaire/diagnostic , Encéphalite/diagnostic , Diagnostic différentielRÉSUMÉ
No disponible
Sujet(s)
Humains , Syndrome malin des neuroleptiques/étiologie , Imipramine/effets indésirables , Bromocriptine/usage thérapeutique , Facteurs de risqueRÉSUMÉ
Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68 percent), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS.
A síndrome neuroléptica maligna (SNM) é um evento adverso potencialmente fatal associado ao uso de antipsicóticos (AP). O objetivo deste estudo foi investigar as características clínicas de cases da SNM e comparar nossos resultados com os publicados na literatura. Uma série de 18 pacientes com diagnóstico confirmado de SNM foram analisados, associando dados demográficos, apresentação clínica, diagnóstico e tratamento. Dois terços dos casos envolveram mulheres com antecedentes psiquiátricos que recebeceram doses relativamente altas de AP. Os sinais e sintomas foram semelhantes àqueles já relatados na literatura e a maioria dos pacientes teve uma recuperação completa, exceto por um caso com desfecho fatal. Houve predomínio de pacientes que usam medicamentos neurolépticos clássicos (68 por cento), porém não houve diferença nas manifestações destes casos em relação àqueles que usavam AP novos. AP mais novos também têm o potencial de causar SNM.
Sujet(s)
Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Neuroleptiques/effets indésirables , Syndrome malin des neuroleptiques/diagnostic , Études transversales , Syndrome malin des neuroleptiques/étiologieRÉSUMÉ
Neuroleptic malignant syndrome (NMS), a potentially fatal adverse reaction to neuroleptics, is known to occur more often in the initial stage of antipsychotic treatment. We describe a patient with chronic schizophrenia who, in a few days after the addition of antituberculotic drugs to his antipsychotic regimen, developed probable NMS without pyrexia. We reasoned that rifampin, a strong hepatic enzyme inducer, decreased the plasma chlorpromazine concentration of the patient, with the result of cholinergic hyperactivity and finally, the symptoms of NMS. Therefore, physicians should be aware of drug interactions and the likelihood of NMS, and consider antipsychotic dose adjustment when prescribing drugs that may influence pharmacokinetic properties of antipsychotics in a patient with schizophrenia receiving long-term antipsychotic treatment.
Sujet(s)
Adulte , Humains , Mâle , Antituberculeux/effets indésirables , Chlorpromazine/effets indésirables , Creatine kinase/sang , Interactions médicamenteuses , Induction enzymatique/effets des médicaments et des substances chimiques , Syndrome malin des neuroleptiques/étiologie , Rifampicine/effets indésirables , Schizophrénie/traitement médicamenteuxRÉSUMÉ
No disponible
We report the case of M., a schizophrenic patient who was treated with high doses of antipsychotics for a long time allowing him to be stable for years. He then decided to give up smoking and two weeks later he suffered a syndrome diagnosed as Neuroleptic Malignant Syndrome with somatic complications. This caused his death two months after the start of the symptoms. We discuss the implications of smoking cessation in the origin of the syndrome due to a lower metabolism of psychotropic medications, which previously had been well tolerated. We conclude that it is important to take into account the smoking and caffeine intake of these patients, as well as other metabolic inductor or inhibitor drugs (AU)
Sujet(s)
Humains , Mâle , Adulte , Schizophrénie/complications , Syndrome malin des neuroleptiques/étiologie , Arrêt de la consommation de tabac , Schizophrénie/traitement médicamenteux , Neuroleptiques/usage thérapeutique , Caféine , NicotineRÉSUMÉ
No disponible
Sujet(s)
Mâle , Sujet âgé , Humains , Syndrome malin des neuroleptiques/diagnostic , Syndrome malin des neuroleptiques/étiologie , Antidépresseurs tricycliques/effets indésirables , Myorelaxants à action centrale/usage thérapeutique , Agonistes de la dopamine/usage thérapeutique , Dantrolène/usage thérapeutique , Antidépresseurs tricycliques/usage thérapeutique , Dépression/traitement médicamenteux , Maladie chroniqueSujet(s)
Mâle , Adulte , Humains , Femelle , Adulte d'âge moyen , Syndrome malin des neuroleptiques/diagnostic , Syndrome malin des neuroleptiques/étiologie , Syndrome malin des neuroleptiques/thérapie , Diagnostic différentiel , Récidive , Facteurs de risque , Syndrome malin des neuroleptiques/complications , Syndrome malin des neuroleptiques/épidémiologie , Syndrome malin des neuroleptiques/physiopathologieRÉSUMÉ
No disponible
Sujet(s)
Femelle , Sujet âgé , Humains , Neuroleptiques/effets indésirables , Benzodiazépines/effets indésirables , Syndrome malin des neuroleptiques/étiologie , Neuroleptiques/usage thérapeutique , Anxiété/traitement médicamenteux , Benzodiazépines/usage thérapeutique , Syndrome malin des neuroleptiques/physiopathologieRÉSUMÉ
Se presenta el caso de un varón de 37 años, esquizofrénico en tratamiento con Clozapina. Es hospitalizado por neurotropenia severa y brusca, evolucionando rápidamente con compromiso de conciencia, agitación psicomotora, temperatura alta e hipotensión refractaria a aporte de volumen. Manejado en la Unidad de Cuidados Intensivos, se asiste a complicaciones renales y respiratorias, destacando la gran hipertonía muscular generalizada. Finalmente, el paciente fallece por paro cardio-respiratorio en asistolía. Se analiza el cuadro de hipertermia y se le relaciona con el uso de neurolépticos, describiéndose la toxicidad por clozapina, que produce neutropenia. Se plantea el diagnóstico diferencial entre el síndrome neuroléptico maligno, la hipertermia maligna y el síndrome serotoninérgico. Por último, se describe el manejo médico de la hipertermia.
Sujet(s)
Adulte , Mâle , Humains , Clozapine/effets indésirables , Syndrome malin des neuroleptiques/étiologie , Maladie aigüe , Neuroleptiques/effets indésirables , Agonistes de la dopamine/usage thérapeutique , Clozapine/pharmacocinétique , Diagnostic différentiel , Hyperthermie maligne/thérapie , Neutropénie/étiologie , Syndrome sérotoninergique/étiologieRÉSUMÉ
Malignant neuroleptic syndrome is a complication of antipsychotic medication use. Clozapine use is also associated with polyserositis and eosinophilia. We report a 17 years old female treated with clozapine, valproic acid, lithium carbonate and lorazepam that consulted in the emergency room for confusion, lethargy, catatonia, rigidity, myalgya and fever. Complete blood count showed eosinophilia. An abdominal CAT scan showed ascites and pleural effusion. Clozapine was discontinued and bromocriptine was started. One week after admission, the patient remained febrile and liver enzymes were elevated. Valproic acid was discontinued. Inflammatory parameters stated to subside and the patient was discharged afebrile days after admission.